Clinical trials: Tight control in early RA pays off in the long run

[1]  T. Zeller,et al.  Summary of NICE guidance , 2011, Heart.

[2]  P. Hannonen,et al.  Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial , 2010, Arthritis research & therapy.

[3]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[4]  A. Ebringer,et al.  Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. , 2010, Autoimmunity reviews.

[5]  S. van der Linden,et al.  Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[6]  S SmolenJosef,et al.  EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2010 .

[7]  G. Kingsley,et al.  A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. , 2010, Rheumatology.

[8]  M. Liang,et al.  Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents , 2009, Annals of Internal Medicine.

[9]  J. Tosh,et al.  Management of rheumatoid arthritis: summary of NICE guidance , 2009, BMJ : British Medical Journal.

[10]  R. Chisin.  Cost-Effectiveness Analysis , 2009, Journal of Nuclear Medicine.

[11]  C. Verweij,et al.  Transcription profiling of rheumatic diseases , 2009, Arthritis research & therapy.

[12]  S. Berney.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial , 2008 .

[13]  Jürgen Reichling,et al.  An Updated Systematic Review of the Pharmacology of Silymarin , 2007, Complementary Medicine Research.

[14]  B. Dijkmans,et al.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis , 2007, Annals of Internal Medicine.

[15]  G. Kingsley,et al.  Joint damage and disability in rheumatoid arthritis: an updated systematic review. , 2003, Clinical and experimental rheumatology.

[16]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[17]  J. Hillert,et al.  Association of rheumatoid arthritis with a dominant DR1/Dw4/Dw14 sequence motif, but not with t cell receptor β chain gene alleles or haplotypes , 2010 .

[18]  P I Terasaki,et al.  High association of an HL-A antigen, W27, with ankylosing spondylitis. , 1973, The New England journal of medicine.

[19]  C. Dollery,et al.  Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. , 1967, Lancet.